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Background: Colon cancer stem cells may drive carcinogenesis and account for chemotherapeutic failure.
Although many markers for these cells have been proposed, there is no complete agreement regarding them, nor
has their presence in the early phases of carcinogenesis been characterized in depth.
Methods: The expression of the putative markers LGR-5 (leucine-rich-repeat-containing G-protein-coupled receptor
5), MSI-1 (Musashi-1) and DCAMKL-1 (doublecortin and calcium/calmodulin-dependent protein kinase-like-1) was
studied in normal colon mucosa (NM), in the precancerous lesions Mucin Depleted Foci (MDF) and in macroscopic
tumours (adenomas) of 1,2-dimethylhydrazine-treated rats. Co-localization between these markers and nuclear
β-catenin (NBC), an attributed feature of cancer stem cells, was also determined. Moreover, since PGE2 could
increase NBC, we tested whether short-term treatment with celecoxib, a COX-2 inhibitor (2 weeks, 250 ppm in the
diet) could reduce the expression of these markers.
Results: LGR-5 expression in NM was low (Labelling Index (LI): 0.22±0.03 (means±SE)) with positive cells located
mainly at the base of the crypts. Compared to NM, LGR-5 was overexpressed in MDF and tumours (LI: 4.7±2.0 and
2.9±1.0 in MDF and tumours, respectively, P<0.01 compared to NM). DCAMKL-1 positive cells, distributed along the
length of normal crypts, were reduced in MDF and tumours. Nuclear expression of MSI-1, located mainly at the
base of normal crypts, was not observed in MDF or tumours. In both MDF and tumours, few cells co-expressed
LGR-5 and NBC (LI: 1.0±0.3 and 0.4±0.2 in MDF and tumours, respectively). Notwithstanding the lower expression of
DCAMKL-1 in tumours, the percentage of cells co-expressing DCAMKL-1 and NBC was higher than in NM (LI: 0.5
±0.1 and 0.04±0.02 in tumours and NM, respectively). MSI-1 and NBC co-localization was not observed. Celecoxib
did not reduce cells co-expressing LGR-5 and NBC.
Conclusions: Based on its prevalent localization at the base of normal crypts, as expected for stem cells, and on
the overexpression in precancerous lesions and tumours, we support LGR-5, but not MSI-1 or DCAMKL-1, as
putative neoplastic stem cell marker. In both MDF and tumours, we identified LGR-5-positive cells co-expressing
NBC which could be a subpopulation with the highest stem cell features.
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Cancer stem cells are increasingly considered as those
cells responsible for colon carcinogenesis as well as the
reason for the failure of chemotherapy [1-4]. Therefore,
an understanding of their biology and their involvement
in the various phases of carcinogenesis is critical to
planning both new chemopreventive and anti-tumour
strategies. While many studies have focused on the iden-
tification of cancer stem cells in advanced tumours and
on their resistance to cytotoxic drugs, their involvement
in the very early phases of carcinogenesis has been less
studied.
Colon carcinogenesis induced in the rat by azoxy-
methane or 1,2-dimethylhydrazine (DMH), is a model
mimicking the sequence of the histopathological and
molecular alterations observed in human pathology
[5,6]. In this experimental setting, the study of precan-
cerous lesions such as Mucin Depleted Foci (MDF) can
allow the identification of the earliest alterations prece-
ding colon tumour development [6]. We have previously
shown that MDF, like tumours, harbour mutations in
the Apc and Ctnnb1 genes, members of the Wnt path-
way and show activation of this signaling [7,8], with, at
least some cells, expressing β-catenin in the nucleus [7].
Accordingly, Wnt activation can be demonstrated as
intracellular, notably nuclear, accumulation of β-catenin
which in the nucleus can activate gene transcription [9].
Interestingly, it has been reported that although APC or
β-catenin mutations can be present in all the cells of a
tumour, not all these cells display nuclear β-catenin
[10,11]. One possible explanation for this “paradox” [12],
is that other factors could contribute to β-catenin nu-
clear translocation. It has been suggested that local
mediators such as COX-derived PGE2 [13] or HGF
(hepatocyte growth factor) present within the micro-
environment could activate the Wnt pathway [11].
Moreover, experimental studies have reported that
cancer cells with stemness ability are those showing high
activity of the Wnt pathway (i.e. nuclear expression of
β-catenin) [11], thus suggesting that the expression of
this marker can aid in the identification of stem cells.
In recent years, many specific epitopes have been sug-
gested as markers of stem cells and, probably, cancer
stem cells, such as CD44, Musashi-1 (MSI-1), CD133,
CD166, DCAMKL-1 (doublecortin and calcium/calmodu-
lin-dependent protein kinase-like-1), ALDH-1 (aldehyde
dehydrogenase 1), LRIG (leucine-rich repeats and
immunoglobulin-like domains-1) and LGR-5 (leucine-
rich-repeat-containing G-protein-coupled receptor 5)
[14-21]. If these markers identify the same population of
cells (i.e. the true stem cells), one would expect an almost
complete overlapping of them. On the contrary, some of
these markers distinguish different populations of cells
[22] suggesting the existence of different stem cellpopulations (quiescent or active), or, perhaps, the need of
more specific markers.
We reported recently that colon carcinomas from
DMH-induced rats which show constitutive activation of
the Wnt pathway, also overexpress the gene for LGR-5
[23], putative stem cell marker in the intestine of mice
and humans and target gene of Wnt. On the contrary,
genes of other proposed stem cell markers, such as
Dcamkl-1, Msi-1 and Prom-1 (CD133), were down-
regulated in DMH-tumours [23]. The expression of
these markers at the protein level as well as the identifi-
cation and localization of the cells expressing them in
the early phases of carcinogenesis has not been yet
studied.
Based on these premises, in order to characterize the
expression of putative stem markers during the early
phases of carcinogenesis, we studied the expression of
LGR-5, MSI-1, DCAMKL-1, CD133 and ALDH1-A1 in
both MDF and tumours by immunohistochemistry.
Since the combination of two markers could improve
the identification of putative neoplastic stem cells , we
also studied the co-localization of some of the above
markers with nuclear β-catenin.
It has been suggested that PGE2 could enhance Wnt
activity, i.e. favor the translocation of β-catenin in the
nucleus [13] conferring stemness features [24], so we
also tested whether a short-term treatment with cele-
coxib, a selective COX-2 inhibitor, could reduce cells
expressing these putative stem cell markers in tumours
from DMH-induced rats.
Methods
Animals and induction of carcinogenesis
Male F344 rats, 4–5 weeks old, were obtained from
Nossan (Milan, Italy) and were housed according to the
European Union Regulations on the Care and Use of
Laboratory Animals [25]; approval of the protocol was
received by the Italian Ministry of Health (ID approval
141/2008-B). Rats were fed throughout the study with a
High Fat (HF) diet based on the AIN-76 diet as reported
[26]. At 6–7 weeks of age rats were treated twice, one
week apart, with subcutaneous injections of DMH
(150 mg/kg × 2 times) to induce colon carcinogenesis
[26]. A group of animals (n=4) was sacrificed after 15
weeks from DMH to harvest the pre-neoplastic lesions
MDF as described [8]. Another group of animals (n=9)
continued the same dietary regimen until 24 weeks after
DMH administration, a time at which macroscopic
tumours (adenomas) were already developed [7,8]. At
this time point, animals were divided into two experi-
mental groups as follows: 1) rats (n=4) continued on the
same experimental diet (controls); 2) rats (n=5) were
administered a diet supplemented with celecoxib (Cele-
brex, Pfizer) at 250 ppm. All animals were sacrificed
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ment period with celecoxib: 2 weeks).
Collection of the samples
After animals were sacrificed, the colon was removed,
washed with saline, longitudinally opened, pinned on a
polystyrene board and fixed in buffered formalin at
room temperature for at least 3 h. Colons from the first
group of animals (sacrificed 15 weeks after DMH) were
stained for 10 min in 1% Alcian blue (AB) in 3% acetic
acid followed by 15 sec of a 0.5% water solution of neu-
tral red (NR) [8], to identify MDF under the microscope.
MDF were marked laterally with permanent ink, dis-
sected together with a portion of apparently normal
mucosa and embedded in paraffin, to be processed for
immunohistochemistry as described below. At sacrifice,
colons from the second group of animals (sacrificed after
26 weeks after DMH) were examined for the presence of
macroscopic tumours and number and size (measured
by a calliper) were registered. Colons were then fixed in
buffered formalin for at least 3 hours and tumours were
excised along with a fragment of adjacent normal mu-
cosa and paraffin-embedded for subsequent immunohis-
tochemistry analysis. Longitudinal sections (4 μm thick)
containing the lesion (MDF or tumour) together with
the surrounding normal mucosa were mounted on
electrostatic-treated slides (SuperfrostW Plus, Medite,
Italy) to be processed for immunohistochemistry as
described below. Given the relative small number of
slides that can be obtained from a rat lesion, it was not
always possible to test each sample (MDF or tumour)
with all the different antibodies and therefore the num-
ber of samples for each marker is not always the same.
Bright-field immunohistochemistry
The sections were processed as described [27] using the
following primary antibodies: LGR-5/GPR49 (rabbit,
monoclonal, Abcam, ab75850); MSI-1 (rabbit, monoclo-
nal, Abcam, ab52865); DCAMKL-1 (rabbit, polyclonal,
Abcam, ab31704), CD133 (rabbit, polyclonal, Abnova,
PAB12663); ALDH1-A1 (rabbit, polyclonal, Abcam,
ab23375); β-catenin (mouse, monoclonal, BD Transduc-
tion Laboratories, catalogue number 610154). Antibodies
were diluted in PBS containing 1% bovine serum albu-
min (BSA) and incubated as follows: LGR-5/GPR49
1:250, 1h at room temperature (RT); MSI-1 1:75, 2h at
RT; DCAMKL-1 1: 200, 1 h at RT; β-catenin 1:1000, over
night at 4°C. The slides were then rinsed twice in PBS,
covered with Biotinylated Goat Anti-Polyvalent as the
secondary antibody (LAB Vision Corporation, CA,
USA). Immunohistochemical staining was performed
using the streptavidin-biotin immunoenzymatic antigen
detection system (Ultravision Large Volume Detection
System Anti-Polivalent, HRP (LAB Vision Corporation,CA, USA) followed by reaction with 3,3’-diaminobenzi-
dine (Liquid DAB Substrate Pack, concentrated; Biogenex,
CA, USA). The slides were weakly counterstained
with Harris’ hematoxylin and observed under a micro-
scope to evaluate the labelling with each antibody identi-
fied by brown staining. Negative controls in which the
primary antibody was omitted were performed in each
experiment. Reactivity evaluation in the normal mucosa
was carried out in crypts separated from the lesion by
an area occupied by at least three crypts. The same
evaluation was carried out for the MDF or tumour
present in the same slide.
Labelling Index (LI) was quantified by determining the
number of labelled cells/total number of cells counted ×
100. Evaluation was performed at 400 × magnification.
The distribution of the labelled cells along the crypts of
the normal mucosa, was evaluated by recording the
number of labelled cells in the three compartments of
the crypt visible in longitudinally sectioned crypts,
ideally divided into three equal parts: lower, mid and
upper.
Fluorescence immunohistochemistry
Paraffin-embedded sections from MDF or tumours to-
gether with the surrounding normal mucosa were used
for co-localization of LGR-5, MSI-1 or DCAMKL-1 with
nuclear β-catenin by immunofluorescence. Sections were
dewaxed with xylene, hydrated through gradations of
ethanol reaching distilled water. Sections were then
immersed in citric acid buffer (pH 6.0) and microwaved
for 3 cycles (5 min each). The slides were then allowed
to cool for 30 min while immersed in citrate buffer,
washed three times with PBS containing 0.05% Tween
20. Sections were then incubated for 1 h with blocking
solution containing 5 mg/ml BSA and 5% Normal Goat
Serum in PBS, pH 7.4 and then incubated with one of
the primary antibodies diluted in blocking solution
according to their incubation time as described above.
Sections were then incubated for 2 h in the dark with
the fluorescent secondary antibody (Alexa FluorW 488
Donkey anti-rabbit IgG, Molecular Probes, Life Tech-
nologies) diluted 1:400 in blocking solution. Thereafter,
sections were incubated with the primary antibody
against β-catenin (1:1000 in PBS, over night at 4°C) and
then incubated for 2 h in the dark with the fluorescent
secondary antibody (Alexa FluorW 594 Rabbit anti-
mouse IgG, Molecular Probes, Life Technologies) diluted
1:400 in blocking solution. Sections were finally coun-
terstained with 4’,6-diamidino-2-phenylindole (DAPI,
1μg/ml) (Vector Laboratories). The analysis of negative
controls (omission of primary antibody) were simulta-
neously performed to exclude the presence of non-
specific immunofluorescence staining. An Olympus
BX40 microscope coupled to analySIS^B Imaging
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images from the examined specimens.
Quantification of the co-localization of LGR-5, MSI-1 or
DCAMKL-1 with nuclear β-catenin by
immunofluorescence technique
For each sample (MDF or tumours together with the sur-
rounding normal mucosa), random fields were analyzed
and images acquired at 400x magnification. Pictures were
then displayed on a computer monitor and identification
of cells co-expressing nuclear β-catenin and LGR-5
(or MSI-1 and DCAMKL-1) (co-localizing cells) was per-
formed by a complete scanning of the image. The total
number of epithelial cells was also registered for each
image. The percentage of co-localizing cells, expressed as
Labelling Index (LI), was calculated as the ratio between
co-localizing cells/ total cells in the field ×100.
Statistical analysis
Differences between the labelling index (LI) of the
lesions (MDF or tumours) and that of the surrounding
normal mucosa (NM) present in the same section and
harvested from the same animal were analysed using
paired t-test; on the contrary, differences between the
lesions (MDF and/or tumours) harvested from different
animals were analysed with unpaired t-test. In both cases
t-tests were two sided. The differences between the dis-
tribution of labeled cells along the crypt for the different
markers were evaluated with chi square analysis. Diffe-
rences were considered significant when P was < 0.05.Figure 1 Histological section of a Mucin Depleted Focus (MDF) proce
Low power magnification of a MDF (red inset) with its surrounding normal
the MDF (red inset in panel A) in which an over-expression of LGR-5 is obs
inset of panel A). Original magnification 400x.Results
Expression of LGR-5, MSI-1, DCAMKL-1, CD133 and
ALDH1-A1 in normal mucosa, MDF and tumours (bright
field immunohistochemistry)
Analysis of LGR-5 expression was carried out in 13
MDF and 15 tumours as well in the adjacent normal
mucosa (NM). On the whole, LGR-5 expression was ab-
sent in most of the colon crypts in the normal mucosa
(Figure 1, panels A and C). However, positive cells were
also observed, located mostly in the lower third of the
crypts (Figure 2, panels A and B), and, more rarely, in
the luminal compartment (Figure 2, panel C). Some
crypts of the normal mucosa showed a diffuse staining
at the lower and middle compartments of the crypt (data
not shown). The labeling index in the normal mucosa
was 0.22±0.03 (means±SE; n=28) (Figure 3). The distri-
bution of labelled cells along the crypt showed that most
of them were located in the lower compartment (69% of
the total labelled cells), while only 18% were in the mid-
dle region and 13% of the total labelled cells were
located in the upper compartment. The labeling index in
the MDF (n=13) and in tumours (n=15) showed
(Figure 3) that the expression of LGR-5 was significantly
increased (P<0.01) in both lesions compared with the
surrounding normal mucosa (Figures 1, 4). The diffe-
rence between the labeling index in MDF and tumours
was not statistically significant (P=0.38). Staining in both
MDF and tumours was heterogeneous, with positive
areas and moderate or negative areas in the same lesion
(Figure 4, panel A); in some cases, the staining was moressed by immunohistochemistry with the LGR-5 antibody. Panel A:
mucosa (original magnification 40x). Panel B: higher magnification of
erved. Panel C: higher magnification of the normal mucosa (green
Figure 2 Expression of LGR-5 in the normal colonic mucosa. Panel A: longitudinally cut crypts in which positive cells in the lower
compartment are visible (within the red inset); original magnification 200x. Panel B: magnification of the red inset in panel A; original
magnification 1000x. Panel C: single stained cell in the luminal compartment of the crypt; original magnification 400x.
Femia et al. BMC Cancer 2013, 13:48 Page 5 of 12
http://www.biomedcentral.com/1471-2407/13/48evident in the upper compartment of the precancerous
lesion or tumour (Figure 4, panel B).
Expression of MSI-1 was determined in 7 MDF and 6
tumours and their surrounding normal mucosa. In the
normal mucosa, we observed intensely stained cells
(in the nucleus or in both nucleus and cytoplasm)
(Figure 5). The labeling index was 0.17±0.03 (mean±SE,
n=13; total cells counted 3782±462; mean±SE). The dis-
tribution of labelled cells along the crypt was similar to0
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Figure 3 LGR-5 expression (as labelling index (LI)) in MDF and
tumours (white bars) and in their respective surrounding
mucosa (NM: black bars). Values are means + SE (n=13 and 15 in
MDF and tumours, respectively). **: P value <0.01 when compared
with the corresponding normal mucosa.that observed for LGR-5 showing that most of them
were located in the lower compartment (67% of the total
labelled cells), while only 24% were in the middle and
9% in the upper compartment. Intensely stained cells
were not present in either MDF or tumours. However,
in 2 out of 7 MDF, we observed a diffuse cytoplasmic
staining not present in the surrounding normal mucosa
(Figure 6). A similar, although weaker, cytoplasmic stai-
ning was also observed in 2 out of 6 tumours analyzed
(data not shown). The remaining MDF and tumour sam-
ples were completely negative.
DCAMKL-1 expression was evaluated in 14 MDF, 6
tumours and their surrounding normal mucosa. In nor-
mal crypts, positive cells were distributed along the
entire length of the crypt, with only a slight prevalence
in the lower part (Figure 7A). There were 47%, 27% and
26% of labeled cells in the lower, mid and upper com-
partments, respectively, a distribution different from that
observed for LGR-5 and MSI-1 (P<0.05). The determin-
ation of the LI in the lesions showed that in tumours the
expression of DCAMKL-1 was significantly lower
(P<0.01) than in corresponding normal mucosa
(Figures 7B and 8); on the contrary, we observed only a
slight, not significant, reduction in MDF compared to
normal mucosa (Figure 8). The difference between the
labeling index in MDF and tumours was not statistically
significant (P=0.10).
Figure 4 Expression of LGR-5 in two different tumours. Panel A: heterogeneous expression of LGR-5 inside a tumour in which positive (white
arrow) and negative (red arrow) areas are present. Panel B: LGR-5 is expressed toward the luminal part. Original magnification 400x.
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but, irrespectively of the experimental conditions used,
they produced an evenly diffuse staining of the sections
that indistinctly marked both the normal mucosa and
the lesions, preventing us from further studying these
two markers.
Co-localization of the LGR-5, MSI-1 or DCAMKL-1 markers
with nuclear β-catenin in normal mucosa, MDF and
tumours (immunofluorescence experiments)
As a further step aiming to identify sub-populations of
cells with the highest stemness features, we carried out
co-localization experiments between each of the threeFigure 5 Expression of MSI-1 in histological sections of normal coloni
nuclear stained cell at the base of one crypt (red arrow). Panel B: magnifica
magnification 400x.markers tested (LGR-5, DCAMKL-1 or MSI-1) and nu-
clear β-catenin in both MDF and tumours. Regarding
LGR-5, we firstly confirmed that the staining of LGR-5
with the immunofluorescence technique was similar to
that observed in bright-field immunohistochemistry
(Figure 9). As a matter of fact, positive cells were
observed in the lower third of sporadic crypts either as
single cell or multiple cells in the normal mucosa
(Figure 9, panels A and B, respectively), while in the
lesions (MDF and tumours), we observed an over-
expression of this marker (Figure 9, panel C). Regarding
β-catenin, we observed cells with nuclear β-catenin
(NBC) accumulation in both MDF and tumoursc mucosa processed by immunohistochemistry. Panel A: single
tion of the area containing the stained cell in panel A. Original
Figure 6 Expression of MSI-1 in a histological section of a MDF
processed by immunohistochemistry. The lesion shows a diffuse
cytoplasmic staining, not present in the normal mucosa. Original
magnification 400x.
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Figure 8 DCAMKL-1 expression (as labelling index (LI)) in the
preneoplastic lesions MDF, tumours (white bars) and in their
respective surrounding mucosa (NM: black bars). Values are
means + SE (n=14 and 6 in MDF and tumours, respectively). **: P
value <0.01 when compared with the corresponding
normal mucosa.
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confirming our previous results [7]. In both MDF (n=12)
and tumours (n=15) cells co-expressing LGR-5 and nu-
clear β-catenin were observed (Figure 9, panel D, white
arrow). The percentage of cells showing co-localization
was not statistically different in MDF and tumours
(Figure 10, right bars, P=0.06). We counted 286±39 cells
in MDF and 709±57 in tumours.
Co-localization experiments between DCAMKL-1 and
nuclear β-catenin (NBC) were also carried out in 10
tumours and in the normal surrounding mucosa (808±128
cells in tumours and 856±180 in normal mucosa), while
MDF were not available for this analysis. In this set of
experiments 4.7±0.8% (means±SE, n=10) of cells expressedFigure 7 Expression of DCAMKL-1 in histological sections of a norma
cells are distributed along the crypt. Panel B: Tumour. Examples of stainedβ-catenin in the nucleus. A representative example of
DCAMKL-1 and nuclear β-catenin co-localization is
reported in Figure 11. Notwithstanding the observed
reduction of DCAMKL-1 positive cells in tumours
compared with the normal mucosa (Figure 8), the per-
centage of cells co-expressing DCAMKL-1 and nuclear
β-catenin was higher in tumours than in the normal
mucosa (LI: 0.39±0.13 in tumours and 0.04±0.02 in
normal mucosa; P<0.01 with paired t-test).
Co-localization experiments between MSI-1 and nu-
clear β-catenin were carried out in a small set of samples
(2 MDF and 6 tumours), since, given the relatively low
expression of MSI-1 in MDF and tumours, we did not
expect to see cells expressing both markers. Accordingly,l colonic mucosa and a tumour. Panel A: Normal mucosa; stained
cells are indicated by white arrows. Original magnification 400x.
Figure 9 Expression of LGR-5 in histological sections of rat colon as assessed by immunofluorescence technique. Panel A: a single
stained cell (white arrow) at the lower compartment of the crypt in normal mucosa. Panel B: multiple positive cells at the base of normal crypts.
Panel C: LGR-5 over-expression in a preneoplastic lesion MDF. Panel D: Magnification of the white inset in panel C showing: LGR-5 expressing
cells (yellow arrow), cells expressing β-catenin in the nucleus (green arrow) and a cell co-expressing LGR-5 and nuclear β-catenin (white arrow).
Original magnification 400x.
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base of normal crypts also in immunofluorescence
(Figure 12, panel A), none of the lesions analysed
showed MSI-1 positive cells, let alone co-localizing cells
(Figure 12, panel B).
Effect of a short treatment with celecoxib (250 ppm in
the diet for 2 weeks before sacrifice) on the percentage
of cells expressing putative CS markers in tumours
Based on the above reported results showing a predom-
inant localization at the base of normal crypts and over-
expression in the precancerous lesions and tumours, we
found that LGR-5 was the best putative stem cell marker
among those analysed. Therefore, we considered as pu-
tative neoplastic stem cells those expressing both LGR-5
and nuclear β-catenin and we verified whether a short-
term treatment with celecoxib, a COX-2 inhibitor, could
reduce the number of such cells. The short period of
treatment was not expected to reduce the number of0
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Figure 10 Expression (as labelling index (LI)) of nuclear β-
catenin (NBC) alone (left bars) or co-expressed with LGR-5
(right bars) in MDF (black bars) and tumours (white bars).
Values are means + SE (n=12 and 15 in MDF and
tumours, respectively).colon tumours; accordingly the number of tumours/rat
was 4.5±0.6 and 3.6±0.7 in controls and celecoxib-
treated rats, respectively (P=0.419). Ten tumours from
controls and 10 tumours from celecoxib-treated animals
were analyzed (see material and methods for the detailed
protocol). The results (Figure 13) show that in tumours
from celecoxib-treated rats there was a slight reduction,
although not statistically significant (P= 0.31) of the cells
with nuclear β-catenin. However, the percentage of cells
showing both LGR-5 and nuclear β-catenin was similar
in the two groups (P=0.56).
Discussion
We wanted to characterize the expression of putative
markers of stem cells in the early phases of colon car-
cinogenesis. To this aim we studied the expression of
LGR-5, MSI-1, DCAMKL-1, CD133 and ALDH1-A1 in
normal mucosa, in MDF (microscopic precancerous
lesions) and in macroscopic tumours (adenomas) of
DMH-induced rats using immunohistochemistry. We
also studied the co-localization of these markers with
nuclear β-catenin, an additional proposed feature of
stemness. To the best of our knowledge, this is the first
study in which these markers are evaluated all together
along the carcinogenesis process in this relevant model
of colon cancer.
LGR-5, a Wnt target gene, was firstly hypothesized as
a stem cell marker because of its profile of expression at
the base of the crypts, compatible with that of a stem
cell [21]. Further investigations with lineage–tracing
experiments confirmed it as probable stem cell marker
in both the small intestine and colon of mice [21]. In the
present study we observed a low expression of LGR-5 in
the normal rat mucosa. Only in some crypts we did
observe positive cells or a diffuse staining localized
mainly in the lower compartment of the crypt, although
a small percent of the total labelled cells (13%) was also
observed in the upper compartment of the crypt.
Figure 11 Representative example of a co-localization experiment between nuclear β-catenin and DCAMKL-1 in histological colonic
sections. Panel A: normal mucosa showing DCAMKL-1 positive cells but no nuclear β-catenin. Panel B: tumour with cells (white arrows) co-
expressing DCAMKL-1 and nuclear β-catenin. Original magnification 400x.
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rare positive cells in the luminal compartment, the low
expression of LGR-5 in the normal mucosa, together
with its prevalent expression at the base of the normal
crypts, agrees with previous studies in humans using
immunohistochemistry techniques as in the present
study [28,29], and suggest that LGR-5 is a marker of
stem cells also in the rat. On the other hand, the seminal
papers locating LGR-5 positive cells at the base of the
crypt [21,30], identified those cells by evaluating LGR-5
gene expression (through RNA in situ hybridization)
or through the expression of a chimeric protein
(LGR-5-EGFP) using an antibody directed against EGFP
[21,30], and thus it is difficult to compare these studies
with ours.
It has been hypothesized that stem cells are more
abundant in tumours than in normal mucosa [2,19] and
we also observed that there was a clear overexpressionFigure 12 Representative example of a co-localization experiment be
sections. Panel A: normal mucosa showing one MSI-1 positive cell at the b
many cells show nuclear β-catenin, but none express MSI-1. Original magnof LGR-5 compared to the normal mucosa in MDF and
tumours. This result, especially the overexpression in
MDF, suggests that LGR-5 expression identifies putative
stem cells, which are involved in the process of carcino-
genesis from the very beginning, i.e. in precancerous
microscopic lesions. We also observed, in agreement
with previous reports in humans [21,28,31], an overex-
pression of LGR-5 in macroscopic tumours (i.e. the
adenomas), confirming overexpression of the LGR-5
gene that we previously reported in DMH-induced colon
tumours [23].
We also studied the expression of two additional stem
cell markers of colonic stem cells, i.e. Musashi-1 (MSI-1)
and doublecortin and calcium/calmodulin-dependent pro-
tein kinase-like-1 (DCAMKL-1). MSI-1, firstly identified
in Drosophila as an RNA binding protein associated with
asymmetric divisions in neural progenitor cells, has been
proposed by Potten and colleagues as a intestinal stem celltween nuclear β-catenin and MSI-1 in histological colonic
ase of the crypt but no nuclear β-catenin. Panel B: tumour in which
ification 400x.
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Figure 13 Expression (as labelling index (LI)) of nuclear
β-catenin (NBC) alone (left bars) or co-expressed with LGR-5
(right bars) in tumours from control rats (black bars) or rats
treated with celecoxib (white bars). Values are means + SE (n=10
and 10 in controls and treated rats, respectively).
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lized in the stem compartment of the intestinal crypts and
is overexpressed in small-intestinal adenomas of the Min
mouse, a genetic model of intestinal carcinogenesis [16].
However, colonic staining in both mouse and human sam-
ples was weak [16]. Here we show that intense nuclear
stained cells were present in the lower third of normal co-
lonic crypts; in contrast, although a diffuse cytoplasmic
overexpression was observed in some MDF and tumours,
the nuclear staining was not observed and the majority of
lesions were negative. Previous studies in normal human
colon mucosa showed both cytoplasmic and nuclear stai-
ning, but the mechanisms regulating the intracellular
localization of this protein are not clear [32]. Altogether,
our results do not support MSI-1 as a robust cancer stem
cell marker. Accordingly, in our previous transcriptomic
analysis of DMH-induced colon tumours, Msi-1 was actu-
ally downregulated compared to normal mucosa [23].
DCAMKL-1, a microtubule-associated kinase expressed
in post-mitotic neurons has also been proposed as a stem
cell marker [18]. However, the stem cell nature of
DCAMKL-1 positive cells has been questioned [33,34].
Accordingly, DCAMKL-1 has been shown to be a specific
marker of tuft, caveolated cells known for many years
[33,35], but poorly characterized until now. Gerbe and col-
leagues studied DCAMKL-1 positive cells in mouse small
intestine demonstrating that they are secretory cells
expressing COX-1, COX-2 and β-endorfin [34]. Our
results show that DCAMKL-1 positive cells were scattered
along the entire length of the crypt in the normal mucosa,
with only a slight prevalence in the lower compartment.
The percentage of DCAMKL-1 cells was slightly, although
not statistically significantly, reduced in MDF, while sig-
nificantly diminished in macroscopic adenomas. This
result is in agreement with Gerbe et al., who report areduction of DCAMKL-1 cells in human adenocarci-
nomas, and with our previous results in DMH-induced
tumours showing a decreased expression of Dcamkl-1
gene [23]. In contrast, Sureban and colleagues found over-
expression in human colon cancers [36].
As a further step aiming at the identification of puta-
tive cells with the most stemness features, we carried
out co-localization experiments with LGR-5, MSI-1,
DCAMKL-1 and nuclear β-catenin, an additional puta-
tive marker of stemness, especially in colon cancer
[10,11]. Previous studies on co-localization between
LGR-5 and nuclear β-catenin, performed in EGFP-
creERT2/Apc flox/flox mice, showed that cells expressing
both LGR-5 (chimeric) and intense nuclear β-catenin
staining give rise to daughter cells which still accumulate
nuclear β-catenin but lose the EGFP-LGR-5 positiveness,
suggesting that the simultaneous expression of both
markers identify cancer stem cells [30]. A positive cor-
relation between LGR-5 and β-catenin expression (both
in cytoplasm and nucleus) has also been reported [28],
but co-localization of both markers in the same histo-
logical sections of a tumour has not been performed so
far, nor has it been studied in the early phases of
carcinogenesis. Here we show that in both MDF and
tumours a sub-population of LGR-5 positive cells
accounting for a small percentage of the lesion cells
(about 1%) exhibits nuclear β-catenin staining, sugges-
ting, on the basis of the previous considerations, that
these cells could be neoplastic stem cells. The finding
that the percentage of these putative neoplastic stem
cells, i.e. of cells expressing the two putative markers, is
unchanged between microscopic MDF and larger ade-
nomas suggests that MDF represent the step in which
stem cells overpopulation already occurs.
Co-localization between DCAMKL-1 and nuclear β-
catenin shows that some cells in the tumours (about
0.4%) co-expressed DCAMKL-1 and nuclear β-catenin;
this figure is similar to that observed for the co-
expression of LGR-5 and β-catenin (Figure 10), but un-
fortunately we do not know whether these cells are the
same. Therefore, also considering the lower number of
DCAMKL-1 positive cells in tumours, a result not in
line with the expected increase for a cancer stem marker,
we can not draw any conclusions on the significance of
these DCAMKL-1-nuclear β-catenin co-expressing cells.
Non-steroidal anti-inflammatory drugs (NSAIDS) are
well documented as having chemopreventive activity in
colon carcinogenesis [37,38]. However, besides their abi-
lity to block COX, their mechanism(s) of action at a mo-
lecular level and the specific population of cells targeted
by these drugs have not been completely clarified. Ac-
cordingly, recent data show that the protective effect of
NSAID may vary depending on genetic and phenotypic
characteristics of the tumour [39]. Previous studies have
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from subjects taking daily aspirin or ibuprofen for up to
25 years [40]. Similarly, nuclear β-catenin translocation
was reduced or abolished in tumours from DMH-
induced rats chronically treated with various NSAIDS
[41]. Accordingly, PGE2, a downstream product of COX-
2, has been shown to enhance Wnt signaling [13]
suggesting that variation in PGE2 within the stem cell
niche may affect cell stemness properties. Recently, it
has been shown that short-term pre-operative treatment
with the NSAIDS indomethacin or celecoxib, (a selective
COX-2 inhibitor), reduces the expression of the stem
cell marker CD133 [42]. Moreover, a short treatment
with the NSAID sulindac induced apoptosis in LGR-5
expressing cells and reduced nuclear β-catenin in the
intestine of Min mice [43], suggesting that PGE2 modu-
lates the expression of these markers and that it may be
possible to down-regulate stemness properties with
pharmacological treatments. To verify this hypothesis we
treated tumour-bearing rats for two weeks with cele-
coxib to determine if the treatment was able to reduce
the percentage of cells with putative stemness features
which we considered those expressing both LGR-5 and
nuclear β-catenin. The dose regimen of celecoxib we
used has been shown to reduce COX-2 activity and
colon carcinogenesis when chronically administered to
AOM-induced rats [44] and is equivalent to the human
dose when adjusted for the appropriate scaling factor
[38]. In vitro studies showed that celecoxib reduces
Wnt-activity in colorectal cancer cells [45]. Our results
show that celecoxib causes only a slight reduction in the
number of cells expressing nuclear β-catenin, which is
not statistically significant; we also observed that it does
not reduce cells co-expressing LGR-5 and nuclear
β-catenin, indicating that, at least in these experimental
conditions, the expression of these putative cancer stem
markers is not affected by treatment.Conclusions
We characterized the expression of three putative markers
of stem cells in the early phases of DMH-induced colon
carcinogenesis in rats. Our results show that LGR-5, but
not MSI-1 or DCAMKL-1, is up-regulated from the very
early phases of colon carcinogenesis i.e. in the microscopic
precancerous lesions MDF. Using immunofluorescence
co-localization we identified in both MDF and tumours a
sub-population of LGR-5 positive cells exhibiting nuclear
β-catenin, which could be putative stem cells with
the highest stemness feature driving the carcinogenesis
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